Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
148 results about "Prostaglandin PGE" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Prostaglandin E2 (PGE-2) is released by blood vessel walls in response to infection or inflammation that acts on the brain to induce fever. The enzyme mPGES-1 is involved in the production of PGE2 and is an important "switch" for activating the fever response.
Method of treating macular degeneration with a prostaglandin derivative
InactiveUS6225348B1Reduce elevated intraocular pressureReduce morbidityBiocideElcosanoid active ingredientsProstaglandin F2alphaProstaglandin PGE
A method of treating age-related macular degeneration in an eye is described, comprising contacting the eye with a therapeutic amount of a prostaglandin F2alpha derivative. The preferred prostaglandin F2alpha derivative is latanoprost, and the preferred dosage is between about 1.5 mug and about 4.5 mug per day per eye.
Owner:PAULSEN ALFRED W
Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
InactiveUS20050250726A1Reduces and prevents non-allergic inflammationOrganic active ingredientsGenetic material ingredientsInflammatory Bowel DiseasesNon allergic
The invention provides methods and compositions for using immunostimulatory nucleic acids to treat non-allergic inflammatory diseases. Non-allergic inflammatory diseases that may be treated according to the methods and products of the invention include psoriasis and inflammatory bowel disease. The invention further provides methods for augmenting a Th1 response to immunostimulatory nucleic acid involving inhibition of prostaglandin-mediated counter-regulatory response.
Owner:UNIV OF IOWA RES FOUND
Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
InactiveUS20060127514A1Increase rate increaseNormalize joint movementBiocideSenses disorderMedicineTriterpenoid
A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Owner:METAPROTEOMICS
Methods of preventing the serotonin syndrome and compositions for use thereof
ActiveUS20080280975A1Reduce incidenceReduce severityBiocideAnimal repellantsSerotoninProstaglandin PGE
The present invention is directed at methods for preventing or minimizing the intensity of the serotonin syndrome in humans and lower animals which comprises administering proserotonergic agents and serotonin surge protectors. The present invention is also directed to pharmaceutical compositions comprising proserotonergic agents and serotonin surge protectors useful for carrying out the method of the present invention.
Owner:RELMADA THERAPEUTICS
Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
InactiveUS20060127515A1Increase rate glucosamineNormalize joint movementBiocideSenses disorderMedicineTriterpenoid
A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Owner:METAPROTEOMICS
Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
InactiveUS20060127517A1Increase rate glucosamineNormalize joint movementBiocideSenses disorderMedicineTriterpenoid
A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Owner:METAPROTEOMICS
Remedies for urinary frequency
InactiveUS20060100195A1Suppress pollakiuriaEffective preventionBiocidePeptide/protein ingredientsEccentric hypertrophyUnstable bladder
The present invention relates to an agent for the treatment and / or prevention of pollakiuria comprising a compound having an antagonism to an EP1 receptor which is a prostaglandin E2 receptor subtype. A compound having an antagonism to an EP1 receptor antagonistically acts on an EP1 receptor which is a prostaglandin PGE2 receptor subtype and significantly shows a suppressive activity for urination frequency in models where pollakiuria is induced. Therefore, it is effective for the treatment and / or prevention of pollakiuria (that which is due to nurogenic bladder, nervous bladder, stimulated bladder, unstable bladder, benign prostatic hypertrophy, etc.).
Owner:ONO PHARMA CO LTD
Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
InactiveUS20050245509A1Improve durabilityImprove actionBiocideSenses disorderGlaucomaProstaglandin a
A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor and prostaglandins as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and / or enhanced each other by combining the Rho kinase inhibitor with prostaglandins. For the administration mode, each drug can be administered in combination or in mixture.
Owner:SANTEN PHARMA CO LTD
Protein kinase modulation by hops and Acacia products
InactiveUS20070154576A1Inhibit the inflammatory responseBiocideSenses disorderKinase activityProtein kinase domain
Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.
Owner:METAPROTEOMICS
Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
This invention provides a compound of the following formula:or the pharmaceutically acceptable salts thereof wherein A is C 1-6 alkylene or -NR1-; Z is C(=L)R2, or SO2R3; U is CH or N; W and Y are independently selected from -CH2-, O, S and -N-R1; m is 1, 2 or 3; q and r are independently 0, 1 or 2; X is independently selected from halogen, C1-4 alkyl, halo-substituted C1-4 alkyl, hydroxy, C1-4 alkoxy, halo-substituted C1-4 alkoxy or the like; n is 1 or 2; L is oxygen or sulfur; R1 is hydrogen or C1-4 alkyl; R2 is hydroxy, C1-6alkyl, halo-substituted C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkoxy, C3-7 cycloalkoxy, C1-4 alkyl(C3-7 cycloalkoxy), -NR4R5 or the like; R3 is C1-6 alkyl or halo-substituted C1-6 alkyl; and R4 and R5 are independently selected from hydrogen, C1-6 alkyl and halo-substituted C1-6alkyl.This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
Owner:PFIZER INC
Prevention of loss and restoration of bone mass by certain prostaglandin agonists
Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis.
Owner:PFIZER INC +1
Pharmaceutical composition for treatment of diseases associated with decrease in bone mass
InactiveUS6891062B2Increase stability and absorbailityIncrease stability and solubilityBiocideOrganic chemistryDiseaseBone formation
A pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient.An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for treatment and / or prevention of diseases associated with decrease in bone mass.
Owner:ONO PHARMA CO LTD
Formulations containing hyaluronic acid
InactiveUS6114314AInhibit synthesisQuick to penetrate into skinBiocideSugar derivativesDiseaseActinic keratoses
Topically applied transdermally quick penetrating (best targeting the epidermis and subsequently remaining there for a prolonged period of time) systemic independent acting, combinations and formulations which employ, combine, or incorporate a therapeutically effective non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis together with an amount of hyaluronic acid and / or salts thereof (for example the sodium salt) and / or homologues, analogues, derivatives, complexes, esters, fragments, and / or sub units of hyaluronic acid to treat a disease and condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women and remain in the skin for a prolonged period of time.
Owner:JAGOTEC AG +1
Protein Kinase Modulation by Hops and Acacia Products
Owner:METAPROTEOMICS
Topical stabilized prostaglandin E compound dosage forms
InactiveUS6841574B2Improve sexual dysfunctionBiocideCosmetic preparationsProstaglandin EProstaglandin PGE
Compounds of prostaglandin E group (PGE compounds) are stabilized as non-aqueous compositions that include the compound together with a bulking agent that can be a non-aqueous liquid or a solid in a sheet, film or powder form. The composition can optionally include a skin penetration enhancer. A non-aqueous, solid dosage form comprises a PGE compound substantially uniformly distributed in a carrier sheet or film.
Owner:NEXMED HLDG INC
Method for treating vitiligo with a prostaglandin analogue
InactiveUS20120251613A1Improves pigmentationReduced maintenance dosageBiocidePeptide/protein ingredientsTransdermal patchSkin surface
A method of stimulating melanogenesis in a skin surface of a patient, by treating the skin surface with a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier. The topical formulation may be a cream, a gel, a lotion, a spray, an ointment, an aqueous solution, a nonaqueous solution, or a transdermal patch. The dermatologically acceptable carrier may contain an oily carrier or an aqueous carrier.
Owner:AGILA SPECIALTIES PVT LTD +1
Composition for preventing or treating periodontal diseases comprising extract from Achyranthis radix or Ulmus cortex
InactiveUS6045800AThorough understandingGood treatment effectCosmetic preparationsBiocideMedicineSuperoxide
The present invention provides a composition for preventing or treating periodontal diseases comprising an extract of Achyranthis radix, Ulmus cortex or a mixture thereof which inhibits the productions of superoxide, prostaglandin, and interleukin (IL-1.beta.) which are inducers for periodontal diseases and inhibits the enzyme activity of collagenase which decomposes collagen protein which is a substrate for the periodontal tissues, and at the same time promotes collagen protein synthesis, thereby treating periodontal diseases efficiently.
Owner:LG HOUSEHOLD & HEALTH CARE LTD
Biomarkers of mild cognitive impairment and alzheimer's disease
A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and / or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and / or serotransferrin protein.
Owner:UNIV OF KENTUCKY RES FOUND
Stabilized prostaglandin formulation
InactiveUS20050031690A1Mitigate gastric ulcerogenic effectGood chemical stabilityPowder deliverySalicyclic acid active ingredientsChemical compoundDissolution
A discrete solid orally deliverable pharmaceutical dosage form comprises a plurality of zones, wherein (a) at least one zone comprises an NSAID; (b) at least one zone, other than a zone comprising the NSAID, comprises HPMC having dispersed therein a prostaglandin type compound in a form of a substantially water-free solid dispersion; (c) the plurality of zones are spatially arranged such that, if there is only one NSAID-containing zone and one prostaglandin-containing zone, these zones are arranged other than as a core and mantle respectively separated by an enteric coating layer; and (d) the HPMC comprises a fraction having particle size smaller than about 53 μm, said fraction exhibiting, upon dissolution in C02-free purified water to form a 1% weight / volume solution, a pH not lower than about 4. An assay method is also provided for selecting suitable lots of HPMC for use in preparing such a dosage form.
Owner:PHARMACIA CORP
Protein kinase modulation by hops and acacia products
Owner:METAPROTEOMICS
Method for treating mucosal disorders
Provided is a method for treating mucosal disorders using a specific prostaglandin compound. The prostaglandin compound induces a conformational change in the tight junction that results in recovery of mucosal barrier function. Accordingly, the prostaglandin compound used herein is useful for the treatment of mucosal disorders.
Owner:SUCAMPO +1
Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Owner:METAPROTEOMICS
Methods and compositions for the synergistic activation of latent HIV
The present invention provides methods and compositions useful for the elimination of latent HIV reservoirs that persist despite HAART. The methods and compositions overcome this latent barrier by inducing the replication of HIV in latently infected T cells while preventing the spread of the newly produced virions to uninfected cells by providing HAART simultaneously. Compositions of the invention comprise an activator of latent HIV expression, such as prostratin, and an inhibitor of histone deacetylase, such as TSA. A surprising finding of this invention is that the inhibitor of the histone deacetylase synergizes the effect of prostratin thus, allowing administering to a patient a lower, non-toxic dose of prostratin.
Owner:THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADS
Pharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists
InactiveUS20080261922A1Preventing and ameliorating sleep-related breathing disorderBiocideNervous disorderNorepinephrine reuptake inhibitorPhosphate
This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Biomarkers of mild cognitive impairment and alzheimer's disease
A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and / or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and / or serotransferrin protein;
Owner:UNIV OF KENTUCKY RES FOUND
Novel biomaterials and a method for making and using same
InactiveUS20080207561A1Quick and easy to manufactureBiocideSenses disorderBiological materialsProstaglandin PGE
A novel biomaterial is disclosed having unique properties that make it useful in ocular drug delivery applications, where the drugs selected from the group consisting of a prostaglandin, a prostamide, a non-steroidal anti-inflammatory drug (NSAID), and a corticosteroid, and mixtures, derivatives, salts and esters thereof.
Owner:ALLERGAN INC
Medicinal compositions
Medicinal compositions for treating or preventing diabetes, rheumatoid, diseases wherein inflammation should be inhibited, diseases wherein alpha-glycosidase should be inhibited, diseases wherein the synthesis of prostaglandin should be inhibited, diseases wherein endotoxin shock should be inhibited, diseases wherein the production of interleukin should be inhibited, diseases wherein the production of heme oxygenase should be induced, and diseases wherein the production of tumor necrosis factor or carcinogenesis should be inhibited, which contain as the active ingredient at least one compound selected from the group consisting of 3,6-anhydrogalactopyranose represented by formula (I), its aldehyde, its hydrate and 2-O-methylated derivatives and 2-O-sulfated derivatives thereof.
Owner:TAKARA HOLDINGS
Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and TGF- beta , optionally in combination with IGF-1
A pharmaceutical composition comprising a prostaglandin such as misoprostol and TGF-B in amounts sufficient to stimulate production of chondrocyte matrix is disclosed which exhibit therapeutic synergy.
Owner:QUEENS UNIV OF KINGSTON
Gene expression in peripheral blood mononuclear cells from children with diabetes
InactiveUS20080227709A1Peptide/protein ingredientsLibrary screeningPeripheral blood mononuclear cellWhite blood cell
The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL-1β antagonists sufficient to spare pancreatic beta cells, including an anti-IL-1β receptor and downstream activators.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Protein kinase modulation by hops and acacia products
ActiveUS20070042063A1Inhibit the inflammatory responseBiocideSenses disorderProtein kinase domainProstaglandin PGE
Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.
Owner:METAPROTEOMICS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com